Uniquely located in the heart of Australia’s largest high-tech precinct, Macquarie brings together more than 40,000 students and 3000 staff in one thriving hub of discovery.
Marilyn Careers has extensive expertise in recruitment across a wide range of industries with particular focus on science, healthcare and technology sectors.
MasterControl quality management software enables regulated companies to achieve compliance and reduce time to market
MedConnet is a post-consultative patient health management company, providing practitioners and patients with the means to optimise the treatment and recovery process through collaboration and wellness education tools.
The MRCF Collaboration, established and managed by Brandon Capital Partners, provides seed and venture capital investment to support the development and growth of Australian and New Zealand life science companies.
The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry.
Medicines Australia represents the discovery-driven pharmaceutical industry in Australia.
MedTec Consulting Ltd delivers complete solutions for all your UK Market Access, Regulatory and Training needs. Having decades of combined experience, we understand the UK healthcare industry and have developed a strong network of contacts across different fields.
MedTEC South Australia operates primarily with an advanced manufacturing agenda, focusing on long term economic development outcomes.
Medtronic is a global healthcare solutions company committed to improving the lives of people through our medical technologies, services, and solutions. Medtronic partner with medical professionals to develop life-changing technologies that improve the way chronic diseases are treated.
Medvet Science Pty Ltd is a company wholly owned by Central Adelaide Local Health Network (CALHN). It is the exclusive research commercialisation agent of CALHN, which includes outstanding health organisations such as The Royal Adelaide Hospital (RAH), The Queen Elizabeth Hospital (TQEH) and SA Pathology.
Melbourne Angels Inc. is an inclusive group of Angel investors investing in high growth, entrepreneurial Australian businesses to realise high returns.
Mesoblast is a world leader in developing innovative cellular medicines. Their clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.
Metabloq Pty Ltd (MetabloQ Pharmaceuticals) is a privately-held biotechnology company developing drugs for difficult-to-treat cancers with a primary focus on triple negative breast cancer. With partners - The Centenary Institute, The University of Sydney and CSIRO - Metabloq are undertaking a drug discovery and development program directed towards a novel target involved in cancer metabolism.
MiniFAB specialises in developing and manufacturing custom micro-engineered solutions that solve complex problems, often integrating microfluidics, polymer and hybrid materials and advanced manufacturing processes.
Minomic International Ltd is an Australian immuno-oncology company that has developed an in vitro diagnostic test for the detection of prostate cancer called MiCheck®. In clinical studies, MiCheck® has demonstrated superior specificity compared with prostate-specific antigen (PSA), which is the current standard of care.
Established in 2008, Mobius Medical is a full service, ISO 9001 certified Australian CRO, providing outstanding clinical trial management and electronic data capture (EDC) services throughout Australia.
Monash University was established in Melbourne, Australia in 1958, believing quality education and research can change the world for the better. Monash has achieved an enviable national and international reputation for research and teaching excellence in a short 50 years.
Monash Vision Group (MVG) is a Melbourne-based collaborative partnership between Monash University, Alfred Health, MiniFab and Grey Innovation. MVG's primary goal is to develop a clinically viable cortical vision prosthesis to restore vision in blind individuals. Since receiving an Australian Research Council (ARC) grant in 2010, MVG has successfully manufactured and tested a wireless, implantable system that can deliver complex electrical signals directly to the visual cortex.